News | Cardiac Imaging | May 10, 2016

MRI Stronger Predictor of Major Adverse Cardiovascular Events than SPECT

Study of 752 patients finds cardiac magnetic resonance better predicts risk at five year follow-up

cardiac magnetic resonance, CMR, SPECT, major adverse cardiovascular events, MACE predictor, Annals of Internal Medicine study

May 10, 2016 — Cardiovascular magnetic resonance (CMR) is a stronger predictor of risk for major adverse cardiovascular events (MACE) than single-photon emission computed tomography (SPECT) at five years follow-up. The findings are published in Annals of Internal Medicine.

CMR is an MRI scan that focuses on the area around the heart. Unlike SPECT, CMR does not involve ionizing radiation and the large CE-MARC (Clinical Evaluation of Magnetic Resonance imaging in Coronary heart disease) study demonstrated that CMR had high diagnostic accuracy, with higher sensitivity and negative predictive value compared with SPECT.

However, data on the prognostic value of CMR remain limited. A predefined objective of CE-MARC was to assess the ability of CMR and SPECT to predict MACE at five-year follow-up. To do so, researchers studied 752 patients from the CE-MARC study who were being investigated for suspected coronary heart disease. The patients were scheduled to undergo CMR and SPECT in random order, followed by X-ray coronary angiography (the reference standard) within four weeks. The investigators followed up with patients every year for five years to assess for MACE.

The researchers found that at five-year follow-up, CMR was a stronger predictor of risk for MACE than SPECT, independent of clinical cardiovascular risk factors, angiography result or initial patient treatment. The researchers conclude that CMR should be considered a robust alternative to SPECT for the diagnosis and management of patients with suspected coronary heart disease.

For more information: www.annals.org

Related Content

Videos | Computed Tomography (CT) | July 19, 2019
Quynh Truong, M.D., MPH, associate professor of radio
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
NorthStar Medical Radioisotopes Completes Construction on Beloit, Wis. Molybdenum-99 Processing Facility
News | Radiopharmaceuticals and Tracers | July 16, 2019
NorthStar Medical Radioisotopes LLC  announced completion of construction on its 20,000-square-foot molybdenum-99 (Mo-...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
Mednax National Cardiac Centers of Excellence Program Highlighted at SCCT 2019
News | CT Angiography (CTA) | July 11, 2019
Mednax Inc. and Mednax Radiology Solutions announced that Chief Medical Officer Ricardo C. Cury, M.D., FSCCT, will...
360 Photos | Ultrasound Imaging | July 11, 2019
This 360 degree photo shows a basic, point-of-care cardiac echocardiogram being performed using a smartphone turned i
Insightec's Exablate Neuro Approved With GE Signa Premier MRI in U.S. and Europe
News | Focused Ultrasound Therapy | July 10, 2019
GE Healthcare and Insightec announced U.S. Food and Drug Administration (FDA) approval and CE mark for Insightec’s...